autosomal recessive limb-girdle muscular dystrophy type 2I
diseaseOn this page
Also known as autosomal recessive limb-girdle muscular dystrophy caused by mutation in FKRPFKRP autosomal recessive limb-girdle muscular dystrophyLGMD-FKRP relatedLGMD2Ilimb-girdle muscular dystrophy due to FKRP deficiencylimb-girdle muscular dystrophy type 2IMDDGC5muscular dystrophy-dystroglycanopathy (Limb-girdle) type C, 5muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5muscular dystrophy-dystroglycanopathy (limb-girdle), type C5
Summary
autosomal recessive limb-girdle muscular dystrophy type 2I (MONDO:0011787) is a disease caused by FKRP (GenCC Definitive), with 2 cohort genes and 8 clinical trials. Top therapeutic interventions include ribitol.
At a glance
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Causal gene: FKRP (GenCC Definitive)
- Cohort genes: 2
- ClinVar variants: 326
- Phenotypes (HPO): 17
- Clinical trials: 8
Clinical features
Epidemiology
Prevalence records
3 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | Europe | Validated | |
| Point prevalence | 1-9 / 1 000 000 | 0.43 | United Kingdom | Validated |
| Point prevalence | 1-9 / 100 000 | 1.85 | Norway | Validated |
Signs & symptoms
Clinical features (HPO)
17 HPO clinical features (Orphanet curated; top 17 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0003236 | Elevated circulating creatine kinase concentration | Very frequent (80-99%) |
| HP:0003560 | Muscular dystrophy | Very frequent (80-99%) |
| HP:0003701 | Proximal muscle weakness | Very frequent (80-99%) |
| HP:0030099 | Reduced muscle fiber alpha dystroglycan | Very frequent (80-99%) |
| HP:0001290 | Generalized hypotonia | Frequent (30-79%) |
| HP:0002515 | Waddling gait | Frequent (30-79%) |
| HP:0003547 | Shoulder girdle muscle weakness | Frequent (30-79%) |
| HP:0003749 | Pelvic girdle muscle weakness | Frequent (30-79%) |
| HP:0005109 | Abnormality of the Achilles tendon | Frequent (30-79%) |
| HP:0008981 | Calf muscle hypertrophy | Frequent (30-79%) |
| HP:0001270 | Motor delay | Occasional (5-29%) |
| HP:0001644 | Dilated cardiomyopathy | Occasional (5-29%) |
| HP:0002359 | Frequent falls | Occasional (5-29%) |
| HP:0002650 | Scoliosis | Occasional (5-29%) |
| HP:0003551 | Difficulty climbing stairs | Occasional (5-29%) |
| HP:0009046 | Difficulty running | Occasional (5-29%) |
| HP:0030092 | Reduced muscle fiber merosin | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | autosomal recessive limb-girdle muscular dystrophy type 2I |
| Mondo ID | MONDO:0011787 |
| MeSH | C564612 |
| OMIM | 607155 |
| Orphanet | 34515 |
| DOID | DOID:0110299 |
| NCIT | C126739 |
| SNOMED CT | 718180000 |
| UMLS | C1846672 |
| MedGen | 339580 |
| GARD | 0012533 |
| Is cancer (heuristic) | no |
Also known as: autosomal recessive limb-girdle muscular dystrophy caused by mutation in FKRP · FKRP autosomal recessive limb-girdle muscular dystrophy · LGMD-FKRP related · LGMD2I · limb-girdle muscular dystrophy due to FKRP deficiency · limb-girdle muscular dystrophy type 2I · MDDGC5 · muscular dystrophy-dystroglycanopathy (Limb-girdle) type C, 5 · muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5 · muscular dystrophy-dystroglycanopathy (limb-girdle), type C5
Data availability: 326 ClinVar variants · 4 GenCC gene-disease records · 4 cell lines.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive disease › autosomal recessive limb-girdle muscular dystrophy › autosomal recessive limb-girdle muscular dystrophy type 2I
Related subtypes (31): epidermolysis bullosa simplex 5B, with muscular dystrophy, autosomal recessive limb-girdle muscular dystrophy type 2A, autosomal recessive limb-girdle muscular dystrophy type 2B, autosomal recessive limb-girdle muscular dystrophy type 2C, autosomal recessive limb-girdle muscular dystrophy type 2H, autosomal recessive limb-girdle muscular dystrophy type 2F, autosomal recessive limb-girdle muscular dystrophy type 2G, autosomal recessive limb-girdle muscular dystrophy type 2E, autosomal recessive limb-girdle muscular dystrophy type 2D, autosomal recessive limb-girdle muscular dystrophy type 2J, autosomal recessive limb-girdle muscular dystrophy type 2K, autosomal recessive limb-girdle muscular dystrophy type 2L, autosomal recessive limb-girdle muscular dystrophy type 2M, autosomal recessive limb-girdle muscular dystrophy type 2O, autosomal recessive limb-girdle muscular dystrophy type 2N, autosomal recessive limb-girdle muscular dystrophy type 2Q, autosomal recessive limb-girdle muscular dystrophy type 2P, autosomal recessive limb-girdle muscular dystrophy type 2T, autosomal recessive limb-girdle muscular dystrophy type R18, autosomal recessive limb-girdle muscular dystrophy type 2U, limb-girdle muscular dystrophy due to POMK deficiency, autosomal recessive limb-girdle muscular dystrophy type 2X, autosomal recessive limb-girdle muscular dystrophy type 2W, autosomal recessive limb-girdle muscular dystrophy type 2Y, autosomal recessive limb-girdle muscular dystrophy type 2R1, muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8, muscular dystrophy, limb-girdle, autosomal recessive 23, muscular dystrophy, limb-girdle, autosomal recessive 26, muscular dystrophy, limb-girdle, autosomal recessive 27, muscular dystrophy, limb-girdle, autosomal recessive 28, muscular dystrophy, limb-girdle, autosomal recessive 29
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
326 retrieved; paginated sample, class counts are floors:
141 uncertain significance, 49 conflicting classifications of pathogenicity, 43 likely pathogenic, 40 pathogenic/likely pathogenic, 29 likely benign, 16 pathogenic, 5 benign/likely benign, 3 benign
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1068020 | NM_024301.5(FKRP):c.229C>T (p.Gln77Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1071118 | NM_024301.5(FKRP):c.540_570dup (p.Cys191fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1395158 | NM_024301.5(FKRP):c.1187dup (p.Ala397fs) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1452218 | NM_024301.5(FKRP):c.1253G>A (p.Trp418Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1903512 | NM_024301.5(FKRP):c.230_234del (p.Gln77fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1920325 | NM_024301.5(FKRP):c.949del (p.Cys317fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1929555 | NM_024301.5(FKRP):c.692G>A (p.Trp231Ter) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 197347 | NM_024301.5(FKRP):c.947C>G (p.Pro316Arg) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2675707 | NM_024301.5(FKRP):c.1020C>G (p.Tyr340Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2675708 | NM_024301.5(FKRP):c.1216C>T (p.Gln406Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2732525 | NM_024301.5(FKRP):c.265C>G (p.Pro89Ala) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 282247 | NM_024301.5(FKRP):c.545A>G (p.Tyr182Cys) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 282866 | NM_024301.5(FKRP):c.162_165dup (p.Phe56fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 284644 | NM_024301.5(FKRP):c.313C>T (p.Gln105Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 287717 | NM_024301.5(FKRP):c.675del (p.Thr226fs) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 289096 | NM_024301.5(FKRP):c.1267del (p.Arg423fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 289473 | NM_024301.5(FKRP):c.970G>T (p.Glu324Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2913953 | NM_024301.5(FKRP):c.1208dup (p.Arg404fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 408721 | NM_024301.5(FKRP):c.1083C>A (p.Tyr361Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4219 | NM_024301.5(FKRP):c.1154C>A (p.Ser385Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4220 | NM_024301.5(FKRP):c.1343C>T (p.Pro448Leu) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4221 | NM_024301.5(FKRP):c.826C>A (p.Leu276Ile) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4222 | NM_024301.5(FKRP):c.387_390dup (p.Asp131delinsThrTer) | FKRP | Pathogenic | no assertion criteria provided |
| 4223 | NM_024301.5(FKRP):c.1486T>A (p.Ter496Arg) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4224 | NM_024301.5(FKRP):c.946C>A (p.Pro316Thr) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4226 | NM_024301.5(FKRP):c.1364C>A (p.Ala455Asp) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 4228 | NM_024301.5(FKRP):c.160C>T (p.Arg54Trp) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 4232 | NM_024301.5(FKRP):c.899T>C (p.Val300Ala) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4233 | NM_024301.5(FKRP):c.919T>A (p.Tyr307Asn) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4235 | NM_024301.5(FKRP):c.1387A>G (p.Asn463Asp) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 15 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| FKRP | Definitive | Autosomal recessive | autosomal recessive limb-girdle muscular dystrophy type 2I | 15 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| FKRP | Orphanet:34515 | FKRP-related limb-girdle muscular dystrophy R9 |
| FKRP | Orphanet:370959 | Congenital muscular dystrophy with cerebellar involvement |
| FKRP | Orphanet:370968 | Congenital muscular dystrophy with intellectual disability |
| FKRP | Orphanet:370980 | Congenital muscular dystrophy without intellectual disability |
| FKRP | Orphanet:588 | Muscle-eye-brain disease |
| FKRP | Orphanet:899 | Walker-Warburg syndrome |
Cohort genes → proteins
2 cohort genes, 2 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 2 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| FKRP | HGNC:17997 | ENSG00000181027 | Q9H9S5 | Ribitol 5-phosphate transferase FKRP | gencc,clinvar |
| STRN4 | HGNC:15721 | ENSG00000090372 | Q9NRL3 | Striatin-4 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| FKRP | Ribitol 5-phosphate transferase FKRP | Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phos… |
| STRN4 | Striatin-4 | Calmodulin-binding scaffolding protein which is the center of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Scaffold/PPI | 1 | 8.6× | 0.225 |
| Other/Unknown | 1 | 0.9× | 0.805 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| FKRP | Other/Unknown | no | LicD/FKTN/FKRP_NTP_transf, LicD_transferase, FKRP_N | |
| STRN4 | Scaffold/PPI | no | WD40_rpt, Striatin_N, WD40/YVTN_repeat-like_dom_sf |
Expression context
Cohort genes with no expression data: 0.
2 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 2 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| cardiac muscle of right atrium | 1 |
| hindlimb stylopod muscle | 1 |
| left ventricle myocardium | 1 |
| left testis | 1 |
| right testis | 1 |
| sural nerve | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| FKRP | 230 | ubiquitous | marker | left ventricle myocardium, cardiac muscle of right atrium, hindlimb stylopod muscle |
| STRN4 | 232 | ubiquitous | marker | left testis, right testis, sural nerve |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| STRN4 | 1,549 |
| FKRP | 1,436 |
Structural data
PDB: 1 · AlphaFold-only: 1 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| FKRP | Q9H9S5 | 8 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| STRN4 | Q9NRL3 | 68.59 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Matriglycan biosynthesis on DAG1 | 1 | 815.7× | 0.001 | FKRP |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| pentitol metabolic process | 1 | 8426.0× | 0.002 | FKRP |
| filtration diaphragm assembly | 1 | 8426.0× | 0.002 | FKRP |
| pentose metabolic process | 1 | 4213.0× | 0.003 | FKRP |
| creatine metabolic process | 1 | 2106.5× | 0.003 | FKRP |
| connective tissue development | 1 | 2106.5× | 0.003 | FKRP |
| oxygen metabolic process | 1 | 2106.5× | 0.003 | FKRP |
| maintenance of protein localization in endoplasmic reticulum | 1 | 1685.2× | 0.003 | FKRP |
| localization of cell | 1 | 1404.3× | 0.003 | FKRP |
| connective tissue replacement | 1 | 1203.7× | 0.004 | FKRP |
| diaphragm development | 1 | 936.2× | 0.004 | FKRP |
| regulation of modification of postsynaptic structure | 1 | 936.2× | 0.004 | STRN4 |
| protein import | 1 | 842.6× | 0.004 | FKRP |
| skeletal muscle fiber differentiation | 1 | 842.6× | 0.004 | FKRP |
| response to alcohol | 1 | 766.0× | 0.004 | FKRP |
| reelin-mediated signaling pathway | 1 | 601.9× | 0.004 | FKRP |
| respiratory system process | 1 | 468.1× | 0.005 | FKRP |
| protein O-linked glycosylation via mannose | 1 | 468.1× | 0.005 | FKRP |
| glial cell differentiation | 1 | 443.5× | 0.005 | FKRP |
| skeletal muscle tissue regeneration | 1 | 443.5× | 0.005 | FKRP |
| negative regulation of hippo signaling | 1 | 351.1× | 0.006 | STRN4 |
| protein tetramerization | 1 | 312.1× | 0.006 | FKRP |
| neuromuscular process | 1 | 263.3× | 0.007 | FKRP |
| basement membrane organization | 1 | 255.3× | 0.007 | FKRP |
| adult walking behavior | 1 | 247.8× | 0.007 | FKRP |
| glycolytic process | 1 | 191.5× | 0.008 | FKRP |
| heart morphogenesis | 1 | 187.2× | 0.008 | FKRP |
| camera-type eye development | 1 | 179.3× | 0.008 | FKRP |
| response to activity | 1 | 162.0× | 0.008 | FKRP |
| response to glucocorticoid | 1 | 162.0× | 0.008 | FKRP |
| bone mineralization | 1 | 135.9× | 0.010 | FKRP |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2
Druggability breadth: 0 of 2 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| FKRP | 0 | 0 |
| STRN4 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 2 | FKRP, STRN4 |
Undrugged target profiles
2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| FKRP | 0 | — |
| STRN4 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 8.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE1/PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05775848 | PHASE3 | ACTIVE_NOT_RECRUITING | Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) |
| NCT04800874 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of BBP-418 in Patients With LGMD2I |
| NCT05230459 | PHASE1/PHASE2 | RECRUITING | A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) |
| NCT02841267 | PHASE1/PHASE2 | COMPLETED | A Trial of PF-06252616 in Ambulatory Participants With LGMD2I |
| NCT05989620 | Not specified | RECRUITING | Long-Term Development of Muscular Dystrophy Outcome Assessments |
| NCT02165358 | Not specified | COMPLETED | Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I |
| NCT03842878 | Not specified | COMPLETED | Natural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I |
| NCT04001595 | Not specified | UNKNOWN | Global FKRP Registry |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RIBITOL | 2 | 2 |